ArticleBMC cardiovascular disorders2025
Impact of CHA₂DS₂-VA score on COVID-19 disease-related outcomes.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Coronavirus disease (COVID-19) pandemic affected millions of people worldwide and caused hundreds of thousands of deaths. The CHA₂DS₂-VASc score is a scoring system used to determine the indication for anticoagulation in patients with atrial fibrillation (AF) and determines the risk of stroke. Previous studies have shown that it predicts mortality in COVID-19 patients well. New guidelines simplified the score as the CHA₂DS₂-VA score, which is free of sex factor. In this study, we planned to investigate the ability of this simplified score in predicting mortality and intensive care unit (ICU) admission in COVID-19 patients. MATERIALS AND
methodsAll patients who were diagnosed with COVID-19 between January 2021 and January 2022 were screened, and patients with accessible data were enrolled. A total of 838 patients were included. The baseline characteristics of the patients and CHA₂DS₂-VA scores were recorded, and their relationship with poor outcomes was investigated. Mann-Whitney U and T-test were used for continuous variables, while logistic regression and ROC analysis were performed to identify predictors of 1-year mortality and ICU admission.
resultsThe mean age of the study population was 53.8 ± 18.5, and 53.6% of them (n = 449) were male. Intensive care unit (ICU) admission was present in 177 (21.1%) patients. 1-year mortality was present in 86 (10.3%) patients. Univariable regression analysis revealed that hypertension, diabetes mellitus, coronary artery disease, heart failure, atrial fibrillation, COPD, CHA
conclusionsAs a result of our study, we found that the CHA₂DS₂-VA score is an independent predictor of 1-year mortality following COVID-19 disease. Cut-off values of the CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.